These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17576839)

  • 21. In vitro activity of fluconazole, voriconazole and caspofungin against clinical yeast isolates.
    Maida CM; Milici ME; Oliveri S
    J Chemother; 2007 Jun; 19(3):277-82. PubMed ID: 17594922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of antifungal susceptibilities to fluconazole and voriconazole of oral Candida glabrata isolates from head and neck radiation patients.
    Burn AK; Fothergill AW; Kirkpatrick WR; Coco BJ; Patterson TF; McCarthy DI; Rinaldi MG; Redding SW
    J Clin Microbiol; 2004 Dec; 42(12):5846-8. PubMed ID: 15583322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom.
    Borman AM; Muller J; Walsh-Quantick J; Szekely A; Patterson Z; Palmer MD; Fraser M; Johnson EM
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
    Marco F; Pfaller MA; Messer S; Jones RN
    Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
    Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
    J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592).
    Yildiran ST; Fothergill AW; Sutton DA; Rinaldi MG
    Mycoses; 2002 Nov; 45(9-10):378-83. PubMed ID: 12421285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.
    Pfaller MA; Zhang J; Messer SA; Brandt ME; Hajjeh RA; Jessup CJ; Tumberland M; Mbidde EK; Ghannoum MA
    Antimicrob Agents Chemother; 1999 Jan; 43(1):169-71. PubMed ID: 9869586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens.
    Guinea J; Recio S; Escribano P; Peláez T; Gama B; Bouza E
    Antimicrob Agents Chemother; 2010 Sep; 54(9):4012-5. PubMed ID: 20566770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin.
    Wildfeuer A; Seidl HP; Paule I; Haberreiter A
    Arzneimittelforschung; 1997 Nov; 47(11):1257-63. PubMed ID: 9428984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
    Pfaller MA; Messer SA; Boyken L; Rice C; Tendolkar S; Hollis RJ; Diekema DJ
    J Clin Microbiol; 2007 Jan; 45(1):70-5. PubMed ID: 17079501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole].
    Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T
    Rev Iberoam Micol; 2005 Jun; 22(2):105-9. PubMed ID: 16107169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii.
    Hazirolan G; Canton E; Sahin S; Arikan-Akdagli S
    Antimicrob Agents Chemother; 2013 Oct; 57(10):4841-7. PubMed ID: 23877683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifungal susceptibility to amphotericin B, fluconazole, voriconazole, and flucytosine in Candida bloodstream isolates from 15 tertiary hospitals in Korea.
    Jung SI; Shin JH; Choi HJ; Ju MY; Kim SH; Lee WG; Park YJ; Lee K;
    Ann Lab Med; 2012 Nov; 32(6):426-8. PubMed ID: 23130342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.
    Pfaller MA; Messer SA; Georgopapadakou N; Martell LA; Besterman JM; Diekema DJ
    J Clin Microbiol; 2009 Dec; 47(12):3797-804. PubMed ID: 19794038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Investigation of in vitro activities of fluconazole, itraconazole and voriconazole against clinical isolates of Blastoschizomyces capitatus (Geotrichum capitatum) by two different methods].
    Sancak B; Alp S; Hasçelik G; Arikan S
    Mikrobiyol Bul; 2009 Apr; 43(2):269-76. PubMed ID: 19621612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.
    Chen SC; Biswas C; Bartley R; Widmer F; Pantarat N; Obando D; Djordjevic JT; Ellis DH; Jolliffe KA; Sorrell TC
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3233-40. PubMed ID: 20530227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the broth microdilution methods of the European Committee on Antimicrobial Susceptibility Testing and the Clinical and Laboratory Standards Institute for testing itraconazole, posaconazole, and voriconazole against Aspergillus isolates.
    Pfaller M; Boyken L; Hollis R; Kroeger J; Messer S; Tendolkar S; Diekema D
    J Clin Microbiol; 2011 Mar; 49(3):1110-2. PubMed ID: 21209166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections.
    Carrillo-Muñoz AJ; Quindós G; Ruesga M; Alonso R; del Valle O; Hernández-Molina JM; McNicholas P; Loebenberg D; Santos P
    J Antimicrob Chemother; 2005 Mar; 55(3):317-9. PubMed ID: 15705637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.